The DURATION Study: reDUcing sedentaRy behAviour to Maintain cogniTIve functiON.

March 1, 2024 updated by: Dr. Harry Prapavessis, Western University, Canada

Determining the Optimal Reduction in Sedentary Behaviour to Reduce Glycemic Variability and Maintain Cognition: a Randomized Control Trial

Rationale: Older adults spend the majority of their time in sedentary behaviours (SB). High amounts of SB have been correlated with reduced cognitive performance. Long periods of time spent sitting results in excessive glycemic variability, potentially contributing to cognitive decline. Reducing/replacing SB with short intermittent bouts of light physical activity have shown positive effects on glycemic variability. Thus, interrupting prolonged sitting with bouts of light physical activity may regulate blood glucose and thus mitigate cognitive decline.

Purpose: This study intends to investigate the appropriate interval frequency of post-prandial SB reduction, by light physical activity needed to optimize total and incremental area under the curve for glucose response in overweight older adults at risk for glucose intolerance with mild cognitive impairment in both lab and free-living environments. Second, this study aims to investigate the acute impact of reducing SB on glycemic variability and its relationship with cognition.

Hypothesis: First, there will be a dose-dependent response of more frequent interruptions of SB (more frequent intervals of light physical activity) with better glycemic control. Second, reducing SB will result in less glycemic variability, which will translate into better levels of cognitive performance.

Methods: Generalized linear mixed models with random intercepts will be used to evaluate the differential effects of the experimental conditions on the selected outcomes.

Study Overview

Detailed Description

This study will be a randomized crossover trial and reported in accordance with CONSORT guidelines. The study will involve a total of three seven-day conditions (2 experimental and 1 control) with a three-week washout period in-between to minimize practice effects for a total intervention period of nine weeks (see figure 1). Each condition will consist of one day supervised in the laboratory followed by six at-home days, following lab protocol as closely as possible.

Participants will be referred to the study by their physician. Interested participants will be asked to contact the researcher by email or phone call. Interested Participants will be invited into the lab for a familiarization session. They will be instructed to avoid caffeine, alcohol and MVPA for 48 hours prior to this session. During this session the following information will be obtained;

  • Written informed consent
  • Height using a stadiometer and weight using a standard beam scale
  • Demographics questionnaire (education, ethnicity, family background, comorbidities)
  • Physical Activity Readiness Questionnaire (PARQ+) (Bredin, Gledhill, Jamnik, & Warburton, 2013)
  • Resting blood pressure- will be measured once on each arm and then twice on the left arm with an automated BP monitor The participants will be educated/familiarized on the following;
  • Cognitive assessments - Cambridge Neuropsychological Test Automated Battery (CANTAB)
  • Fitting with an inclinometer (activPAL4)

Participants will be visited at their home ~72hrs prior to each condition to be fitted with the CGM and ActivPal. They will also be instructed to avoid caffeine, alcohol and MVPA for 48 hours prior to each of the three conditions. Dinner will be consumed between 7:00 and 9:00 pm, allowing for a 10 hour fast prior to the experimental condition the next morning. All participants will be instructed to arrive at the laboratory (with minimal activity during commute) at approximately 7:00 am. Upon arrival, participants will be asked to use the washroom and then rest for 30 minutes preceding a blood pressure measurement and first cognitive assessment. The participants will undergo the CANTAB cognitive assessments (at ~7:30 am) before meal consumption. A standardized breakfast meal will be consumed at 8:00 am, followed by lunch at 12:00 pm and dinner at 5:00 pm. Participants will be allotted 20 minutes for full meal consumption. The CANTAB cognitive assessments will then be re-administered at approximately 7:30 pm. Participants will be supervised throughout the conditions to ensure adherence to the protocols and will be permitted to watch DVDs, read books, magazines, newspapers, talk and/or work on a laptop computer. However, what they do during the first condition will be documented and then replicated for the remaining experimental conditions. Intensity of the bout intervals will be kept to an RPE of 6-9 using the Borg RPE scale.

Once the 12- hour laboratory component is complete, participants will be sent home (still wearing the CGM and activPAL) with the intension of replicating the laboratory-based protocol after each meal in their own free-living environment. Participants will track their mealtimes by sending photos to the researcher before consumption during the 6 at home days. The researcher will then go to the participants house on the last day (day 7) of each condition to re-administer the CANTAB cognitive assessments and collect the CGM, and activPal. There will then be a 3-week washout period, followed by replication of protocol for the remaining two conditions.

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • London, Ontario, Canada
        • The University of Western Ontario

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥ 65 years
  • Have a caregiver that works with you at least 20 hours a week (needs to be present for the familiarization session (explained below) and drop-off and pick-up from lab sessions)
  • Diagnosis of diabetes by a healthcare provider (e.g. family doctor).
  • Diagnosis of MCI by a healthcare provider
  • Self-report being physically inactive (not meeting the current PA guidelines of 150 min MVPA/week)
  • Self-report being sedentary- (defined as self-reported sedentary time ≥ 7 h/day)
  • Able to walk one block without an assistive device
  • Own a smartphone with unlimited outgoing text messages and access to internet connection. The smartphone must be either iphone 7 (with iOS of 12.2 or higher) or Android operating system 5 or higher to allow for Libre View mobile application compatibility.
  • Able to read, write and understand English

Exclusion Criteria:

  • Currently smoke
  • Depression (Geriatric Depression Score short-form > 6 (GDS)) (Yesavage, Brink, Rose, & et al, 1983).
  • Medication: hypoglycemics; antilipidemics; antidepressants; beta blockers; anti-anxiety agents
  • Peri-menopausal or menopausal women (must be post-menopausal)
  • Excessive alcohol consumption (> 8 points on the Alcohol Use Disorders Identification Test)
  • Uncontrolled hypertension (measured systolic > 140 mmHg or diastolic > 90 mmHg)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control (CON)
1) Condition A (CON): This will be the control condition. It will consist of uninterrupted sitting from 8 am until 7 pm, only rising from the chair to void.
Experimental: one 10 minute bout - (LONG)
will consist of completing one 10-minute bout of light intensity walking (RPE 6-9) 30 minutes post-prandial. Participants will rise from their seated position to walk ~10 metres to a treadmill to perform this bout. The participant will repeat this after lunch and dinner, for an accumulated total of 30 minutes of light walking.
replacing sitting with light walking bouts at different frequencies/durations
Experimental: four 2.5 minute bouts SHORT
will consist of interrupting sitting with four 2.5-minute bouts of light walking at 30 minutes, 60 minutes, 90 minutes and 120 minutes post-prandial. Participants will rise from their seated position to walk ~10 metres to a treadmill to perform these bouts. The participant will repeat this after breakfast, lunch and dinner for an accumulated total of 30 minutes of light walking.
replacing sitting with light walking bouts at different frequencies/durations

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glycemic Variability
Time Frame: 1-7 days
to investigate the appropriate interval frequency of post-prandial SB reduction, by light physical activity needed to optimize total and incremental area under the curve for glucose response in overweight older adults at risk for glucose intolerance with mild cognitive impairment in both lab and free-living environments.
1-7 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognition
Time Frame: 1-7 days
CANTAB will be used to measure change in cognitive function. This is a computerized battery of neuropsychological tests utilizing touch sensitive screen technology that has been shown to be highly sensitive and a precise measure of cognitive function, correlated to neural networks (CANTAB, 2017). The following three cognitive domains were selected for testing; attention and psychomotor function (Motor Screening Task (MOT) and Rapid Visual Information Processing (RVP)), memory (Delayed Matching to Sample (DMS)) and executive function (Intra-Extra Dimensional Set Shift (IED))
1-7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Harry Prapavessis, Ph.D, Western University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2025

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

March 9, 2020

First Submitted That Met QC Criteria

March 24, 2020

First Posted (Actual)

March 26, 2020

Study Record Updates

Last Update Posted (Estimated)

March 5, 2024

Last Update Submitted That Met QC Criteria

March 1, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glucose Intolerance

Clinical Trials on interrupting sedentary behaviour with light physical activity

Subscribe